KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Depreciation and Depletion (2016 - 2025)

Gilead Sciences (GILD) has disclosed Depreciation and Depletion for 17 consecutive years, with $90.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation and Depletion fell 5.26% year-over-year to $90.0 million, compared with a TTM value of $370.0 million through Dec 2025, down 2.89%, and an annual FY2025 reading of $370.0 million, down 2.89% over the prior year.
  • Depreciation and Depletion was $90.0 million for Q4 2025 at Gilead Sciences, roughly flat from $90.0 million in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $98.0 million in Q2 2024 and bottomed at $78.0 million in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $87.8 million, with a median of $90.0 million recorded in 2021.
  • The sharpest move saw Depreciation and Depletion fell 7.78% in 2022, then grew 18.07% in 2024.
  • Year by year, Depreciation and Depletion stood at $90.0 million in 2021, then decreased by 7.78% to $83.0 million in 2022, then grew by 9.64% to $91.0 million in 2023, then rose by 4.4% to $95.0 million in 2024, then dropped by 5.26% to $90.0 million in 2025.
  • Business Quant data shows Depreciation and Depletion for GILD at $90.0 million in Q4 2025, $90.0 million in Q3 2025, and $93.0 million in Q2 2025.